###begin article-title 0
###xml 30 31 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Expression of Na,K-ATPase-beta1 subunit increases uptake and sensitizes carcinoma cells to oxaliplatin
###end article-title 0
###begin title 1
Purpose
###end title 1
###begin p 2
###xml 387 388 381 382 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 99 104 <span type="species:ncbi:9606">human</span>
The ovarian carcinoma subline A2780/C10B (C10B) is an oxaliplatin resistant clone derived from the human ovarian carcinoma cell line A2780. The C10B cells are characterized by mesenchymal phenotype, decreased platinum uptake and increased glutathione levels (Hector et al. in Cancer Lett 245:195-204, 2007; Varma et al. in Oncol Rep 14:925-932, 2005). Na,K-ATPase-beta subunit (Na,K-beta1) functions as a cell-cell adhesion molecule in epithelial cells and is reduced in a variety of carcinoma cells that show mesenchymal phenotype. The purpose of this study is to evaluate the relationship between Na,K-beta expression and sensitivity to oxaliplatin.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 68 69 65 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 167 168 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 274 275 258 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 289 290 270 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 127 130 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 170 173 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
Cell lines used include A2780, C10B, C10B transfected with Na,K-beta1 (C10B-Na,K-beta) and a canine kidney carcinoma cell line MSV-MDCK also transfected with Na,K-beta1 (MSV-MDCK-beta subunit). Cytotoxicity studies were performed by sulforhodamine-blue assay. The Na,K-alpha1 and Na,K-beta1 subunit localization and expression were by immunofluorescence microscopy and Western blot analysis. Platinum accumulation measurements were by atomic absorption spectrophotometry.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 53 54 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 97 98 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 294 295 285 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 404 407 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
C10B cells express highly reduced levels of Na,K-beta1 subunit. Exogenous expression of Na,K-beta1 increased platinum accumulation and sensitized C10B cells to oxaliplatin. The pharmacological inhibitor of Na,K-ATPase ouabain did not alter the oxaliplatin accumulation indicating that Na,K-beta1 sensitizes cells in a Na,K-ATPase enzyme activity independent manner. These findings were also confirmed in MSV-MDCK-beta subunit cells.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 78 79 75 76 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 296 297 290 291 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
This study for the first time reveals that reduced expression of the Na,K-beta1 protein is associated with oxaliplatin resistance in cancer cells and demonstrates a novel role for this protein in sensitizing the cells to oxaliplatin. This study suggests a potentially important role for Na,K-beta1 in both prognosis and therapy of oxaliplatin resistant malignancies.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 562 563 562 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 565 567 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 824 825 824 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 827 829 827 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 831 833 831 833 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 1245 1247 1245 1247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1249 1251 1249 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1373 1375 1373 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1377 1379 1377 1379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1595 1597 1595 1597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1599 1601 1599 1601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 1603 1605 1603 1605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 899 904 <span type="species:ncbi:9606">human</span>
###xml 1011 1016 <span type="species:ncbi:9606">human</span>
Platinum drugs are central to many chemotherapy regimens in cancer treatment. Oxaliplatin is active in many cisplatin responsive cancers including ovarian [24], and approved for colon cancer, a cisplatin non-responsive cancer, because of its unique activity when administered in combination with 5-fluorouracil [35]. Like other forms of chemotherapy while responsive initially, platinum drug treatment can eventually result in tumor resistance. Resistance to platinum drugs, has been extensively studied especially for cisplatin and is multifactorial in nature [2, 12]. Mechanisms of platinum drug resistance include drug accumulation deficiencies, intracellular detoxification, increased repair of DNA-Platinum adducts, increased tolerance to the drug and alterations in downstream signaling affecting cell death pathways [2, 12, 25]. A variety of drug resistant carcinoma cell models including of human ovarian, colon, bladder and lung have been used in these studies. Studies from our laboratory using A2780 human ovarian carcinoma cells indicated that the mechanisms of oxaliplatin resistance are similar to those for cisplatin, and primarily include decreased drug accumulation and increased detoxification by conjugation with glutathione [15, 16]. These studies suggested that reduced DNA-Platinum adduct formation was a consequence of the reduced drug accumulation [15, 16]. Additionally, recent studies from our laboratory and those of others using A2780 ovarian carcinoma cells suggest that the extracellular matrix (ECM) may play a role in the resistance to oxaliplatin and cisplatin [16, 30, 34].
###end p 10
###begin p 11
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 554 556 554 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 688 690 688 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 830 832 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 994 995 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 1309 1311 1309 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1426 1428 1426 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 1574 1575 1571 1572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1577 1579 1574 1576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1678 1680 1675 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 799 804 <span type="species:ncbi:9606">human</span>
While mechanisms of drug resistance are extensively studied, factors that sensitize cancer cells to cytotoxic drugs are less developed and poorly understood. Epithelial to mesenchymal transition (EMT) is one of the mechanisms involved in carcinoma cell progression to metastatic and drug resistant cancer [32]. During this transition, epithelial cells lose morphology and expression of epithelial markers such as cytokeratins, and show fibroblastic phenotype characterized by increased expression of mesenchymal markers such as vimentin and fibronectin [13]. In colorectal carcinoma cell lines KM12L4 and HT-29, induction of EMT was reported to be associated with oxaliplatin resistance [36]. The A2780/C10B (C10B) is a clonal subline, selected for resistance to oxaliplatin from the parental A2780 human ovarian carcinoma cells [16]. As reported previously [16], the C10B clone was isolated using limit-dilution procedure from A2780/C10, an oxaliplatin resistant cell line derived from A2780 [9] by plating of single cell suspension and isolating a colony of >50 cells that was expanded. The C10B cells are spindle shaped and fibroblast-like in morphology as described in EMT with a lack of epithelial membrane antigen (EMA), whereas the parental cells exhibit epithelial phenotype with the presence of EMA [16]. Consistent with the phenotype, C10B cells have elevated levels of vimentin, and reduced levels of cytokeratins [16]. Affymetrix gene expression analysis demonstrated that the C10B cells have high expression of collagen 6, matrix metalloproteinases and TGF-beta2 [34]. While it is reported that chemoresistance to paclitaxel induces EMT in ovarian carcinoma cells [21], this phenomenon is not well documented in this tumor type for oxaliplatin resistance.
###end p 11
###begin p 12
###xml 233 234 229 230 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 246 247 238 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 257 258 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 269 270 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 283 284 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 328 329 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 399 400 374 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 425 427 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 458 459 433 434 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 475 476 450 451 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 657 659 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 778 780 749 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 816 818 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 890 891 858 859 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1006 1008 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1010 1012 978 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1024 1025 989 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1110 1112 1075 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1178 1180 1143 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1182 1184 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1211 1212 1173 1174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1324 1325 1286 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1327 1329 1289 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1351 1353 1313 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1432 1433 1391 1392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 798 803 <span type="species:ncbi:9606">human</span>
###xml 1283 1286 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
The Na,K-ATPase, also known as the sodium pump is a plasma membrane bound, oligomeric enzyme localized to the basolateral plasma membrane in most epithelial cells. It is composed of two essential, non-covalently bound subunits, alpha1 (Na,K-alpha1) and beta1 (Na,K-beta1). Na,K-alpha1 is the catalytic subunit, whereas Na,K-beta1 is involved in the translation, stability and transport of Na,K-alpha1 on the plasma membrane [27]. Na,K-ATPase transports two K+ in and three Na+ out at the expense of one molecule of ATP. It not only maintains intracellular ion homeostasis but is also critical for the maintenance of polarized phenotype of epithelial cells [26]. Ouabain is a well studied pharmacological inhibitor of Na,K-ATPase which specifically binds to Na,K-alpha with an IC50 of 10 nM in most human cell types [19]. Well differentiated epithelial cells express high levels of Na,K-beta1, whereas poorly differentiated carcinoma cells with mesenchymal phenotype express reduced levels of this protein [11, 28]. Na,K-beta1 levels were drastically reduced in highly motile and invasive carcinoma cell lines [11] and correlate with their invasiveness and metastatic potential [18, 28]. Restoration of Na,K-beta1 in Moloney Sarcoma virus transformed Madin-Darby canine kidney cells (MSV-MDCK) suppressed motility, invasion [6, 28] and tumorigenicity [18]. These studies strongly indicated a functional link between reduced Na,K-beta1 expression and cancer progression.
###end p 12
###begin p 13
###xml 76 77 73 74 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 201 202 195 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 334 335 325 326 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 458 459 443 444 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 494 495 476 477 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
In this study, we tested the hypothesis that reduced expression of Na,K-beta1 in C10B is associated with oxaliplatin resistance by evaluating the relationship between oxaliplatin sensitivity, Na,K-beta1 expression, and platinum accumulation in C10B cells in comparison with the parental A2780 and C10B cells transfected with Na,K-beta1 subunit (C10B-Na,K-beta). Results presented here reveal that the resistant C10B cells have reduced expression of Na,K-beta1. Exogenous expression of Na,K-beta1 results in increased oxaliplatin uptake and cellular sensitivity to the drug, independent of Na,K-ATPase enzyme activity.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
Drugs
###end title 15
###begin p 16
Oxaliplatin was a gift from Dr. Paul Juniewicz of Sanofi-Synthelabo (Malvern, PA).
###end p 16
###begin title 17
Cell lines
###end title 17
###begin p 18
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 292 293 289 290 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 376 377 367 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 728 729 716 717 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 901 902 886 887 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 990 992 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 361 366 <span type="species:ncbi:9606">human</span>
###xml 702 708 <span type="species:ncbi:9913">bovine</span>
###xml 816 819 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 872 875 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 904 907 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
The ovarian carcinoma cell line A2780 was a gift from Dr. Ozols (Fox Chase Cancer Center, Philadelphia, PA). The oxaliplatin resistant C10B subline was derived as a single cell clone from a previously described A2780/C10 cell line [9]. A pooled clone of C10B cells stably expressing Na,K-beta1 (C10B-Na,K-beta) was generated by transfecting the C10B cells with human Na,K-beta1 cDNA in a mammalian expression vector with neomycin resistance (pcDNA3.1 from Invitrogen, Carlsbad, CA). C10B cells transfected with the empty vector (C10B-Vector) were used as a control. The ovarian carcinoma cell lines and the C10B-Na,K-beta cells were maintained in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum (FBS) and 1% l-glutamine (Invitrogen, Grand Island, NY). Other cell lines used in the study included MSV-MDCK cells stably transfected with pcDNA3.1 vector (MSV-MDCK-vector) or Na,K-beta1 (MSV-MDCK-beta subunit). Generation of these cell lines has been described previously [28]. These cells were grown in DMEM with 10% FBS, 1% penicillin and streptomycin and 200 mug/ml neomycin.
###end p 18
###begin title 19
Cytotoxicity assays
###end title 19
###begin p 20
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 358 361 358 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 380 383 380 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
Cytotoxicity analysis was carried out using sulforhodamine-blue (SRB) assay as described previously [16]. Cells were continuously exposed to oxaliplatin for 72 h, fixed and subjected to the SRB assay. The optical density (OD) was read at 570 nm (EL309 Automated Microplate Reader, Bio-Tek Instruments, Winooski, VT) and percent survival was determined as [OD570 (treated cells)/OD570 (untreated cells)] x 100.
###end p 20
###begin title 21
Platinum accumulation
###end title 21
###begin p 22
###xml 151 153 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
Cells were exposed to oxaliplatin (100 muM) for 2 h, washed thoroughly with PBS and total intracellular platinum was measured as previously described [15]. For this drug exposed cells were trypsinized and centrifuged into a pellet and lysed in 0.5 ml of 0.1% Triton X-100 and 0.2% nitric acid overnight and sonicated for 1 min. Platinum in the cell lysate was measured by graphite furnace atomic absorption spectrophotometry with Zeeman background correction (PE 4100ZL, Norwalk, CT). Protein was measured using the Bradford assay. In experiments aimed at Na,K-ATPase inhibition, cells were pretreated with ouabain (50 muM) for 15 min prior to oxaliplatin exposure with a continued incubation with ouabain (50 muM) also during the exposure to oxaliplatin.
###end p 22
###begin title 23
Immunofluorescence
###end title 23
###begin p 24
###xml 104 105 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 119 120 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 165 169 <span type="species:ncbi:9925">goat</span>
###xml 175 180 <span type="species:ncbi:10090">mouse</span>
Cells grown on cover slips were fixed with chilled methanol, incubated with antibodies against Na,K-beta1 or Na,K-alpha1 and stained with Alexa Fluor 488 conjugated goat anti-mouse antibody (Invitrogen). Samples were excited with an argon laser, and the light emitted around 519 nm was recorded. Images were obtained using a confocal microscope Leica TCS SP5 (Leica Microsystems Inc., Bannockburn, IL).
###end p 24
###begin title 25
Reverse transcription and quantitative real-time PCR
###end title 25
###begin p 26
Total RNA was isolated from A2780, C10B and C10B-Na,K-beta cells using the RNA Aqueous kit (Ambion, Austin, TX). RNA concentration was measured using the Nanodrop Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). First strand cDNA was generated from total RNA using the High Capacity cDNA kit (Applied Biosystems, Foster City, CA). One microgram of RNA was reverse transcribed to cDNA according to the manufacturer's protocol. Quantitative RT-PCR analysis of ATP1B1 was performed using the ATP1B1 gene specific TaqMan MGB assay and TaqMan universal master mix on an ABI 7900HT System from Applied Biosystems. The 'comparative threshold' method was used to calculate relative gene expression. Values were normalized against 18S rRNA.
###end p 26
###begin title 27
Western blot analysis
###end title 27
###begin p 28
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1156 1157 1145 1146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1172 1173 1157 1158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Immunoblot analysis was performed as described previously [28]. Cells were lysed in a buffer containing 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM sodium glycerolphosphate, 1 mM sodium orthovanadate, 1 mM PMSF, and 5 mug/ml each of antipain, leupeptin and pepstatin. The lysates were sonicated, and clarified by centrifugation at 13,000 rpm for 10 min at 4degreesC. Total protein was estimated from the supernatants using the Bio-Rad DC reagent (Bio-Rad, Hercules, CA) as per manufacturer's instructions. Total protein (50 mug) was resolved on SDS-PAGE and transferred to nitrocellulose membrane (Schleicher & Schuell, Keene, NH). Immunoblotting was performed using a primary antibody, and HRP-conjugated secondary antibody diluted in tris-buffered saline containing 5% non-fat dried milk and 0.1% Tween20. The proteins were detected by using the enhanced chemiluminescence lighting system according to the manufacturer's recommendations (PerkinElmer Life and Analytical Sciences, Boston, MA). The bands from two independent experiments were quantified using GeneTools software from PerkinElmer, Waltham, MA. Na,K-beta1 and Na,K-alpha1 antibodies were a gift from Dr. William James Ball Jr., University of Cincinnati, Cincinnati. Anti-fibronectin and E-cadherin antibodies were from BD Biosciences, San Jose, CA. beta-Actin (Sigma, St. Louis, MO) was used as a loading control.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 100 101 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
Significance of differences in cytotoxicity and platinum accumulation was evaluated using Student's t test (Systat Software Inc., Richmond, CA).
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 23 24 20 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Expression of Na,K-beta1 in A2780, C10B and C10B-Na,K-beta cells
###end title 32
###begin p 33
###xml 44 45 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 69 70 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 107 108 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 142 143 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 195 196 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 238 239 226 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 302 303 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 407 408 391 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 446 447 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 522 523 503 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 554 555 531 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 569 570 543 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 635 636 606 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 649 650 620 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 749 750 717 718 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 757 758 725 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 914 915 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 953 954 918 919 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1063 1064 1028 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1145 1147 1110 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 1312 1313 1277 1278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1428 1429 1393 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1451 1452 1413 1414 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1587 1588 1549 1550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1652 1653 1611 1612 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1693 1699 1652 1658 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 1699 1700 1658 1659 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1882 1887 1838 1843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel</italic>
###xml 1889 1890 1845 1846 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1950 1951 1906 1907 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 2074 2077 2030 2033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar</italic>
###xml 1699 2084 1658 2039 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34"><bold>a</bold> Immunoblot analysis of Na,K-ATPase subunits, fibronectin, E-cadherin and actin in parental A2780, C10B and C10B-Na,K-&#946; cells. Densitometric quantitations are included under each <italic>panel</italic>. <bold>b</bold> Relative mRNA expression using quantitative real-time PCR. <bold>c</bold> Morphological characterization and localization of Na,K-ATPase subunits by phase contrast and epifluorescence microscopy. <italic>Bar</italic> 20&#160;&#956;m</p>
###xml 1699 2084 1658 2039 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34"><bold>a</bold> Immunoblot analysis of Na,K-ATPase subunits, fibronectin, E-cadherin and actin in parental A2780, C10B and C10B-Na,K-&#946; cells. Densitometric quantitations are included under each <italic>panel</italic>. <bold>b</bold> Relative mRNA expression using quantitative real-time PCR. <bold>c</bold> Morphological characterization and localization of Na,K-ATPase subunits by phase contrast and epifluorescence microscopy. <italic>Bar</italic> 20&#160;&#956;m</p></caption>
###xml 2084 2084 2039 2039 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2009_985_Fig1_HTML" id="MO1"/>
###xml 1693 2084 1652 2039 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="34"><bold>a</bold> Immunoblot analysis of Na,K-ATPase subunits, fibronectin, E-cadherin and actin in parental A2780, C10B and C10B-Na,K-&#946; cells. Densitometric quantitations are included under each <italic>panel</italic>. <bold>b</bold> Relative mRNA expression using quantitative real-time PCR. <bold>c</bold> Morphological characterization and localization of Na,K-ATPase subunits by phase contrast and epifluorescence microscopy. <italic>Bar</italic> 20&#160;&#956;m</p></caption><graphic position="anchor" xlink:href="280_2009_985_Fig1_HTML" id="MO1"/></fig>
A2780 cells express high levels of Na,K-beta1 compared to C10B (Fig. 1a). Exogenous expression of Na,K-beta1 in C10B cells increased Na,K-beta1 levels comparable to its expression in A2780 (Fig. 1a). There was a 50% reduction in Na,K-beta1 transcript levels in C10B cells compared to A2780 cells (Fig. 1b) consistent with the reduction at the protein level. There was no significant change in the Na,K-alpha1 levels in all these cell lines (Fig. 1a). However, they were similar between C10B and C10B-Na,K-beta cells (Fig. 1a). As expected both Na,K-alpha1 and Na,K-beta1 were localized to the plasma membrane in A2780 and C10B-NaK-beta1 cells (Fig. 1c). Consistent with the immunoblot analysis, C10B cells revealed highly reduced levels of Na,K-beta1 (Fig. 1c). Morphologically, C10B cells showed a fibroblastic phenotype, whereas, the A2780 were adherent to each other and showed epithelial like morphology (Fig. 1c). Interestingly, following Na,K-beta1 expression C10B cells grew adherent to each other and appeared morphologically similar to A2780 cells (Fig. 1c). Expression of mesenchymal marker fibronectin is one of the hallmarks of EMT [17]. Consistent with the fibroblastic morphology, the C10B cells expressed high levels of fibronectin which was present at a lower level in parental A2780 cells (Fig. 1a). On the other hand, the expression of the epithelial marker, E-cadherin was greatly reduced in C10B cells (Fig. 1a). Although Na,K-beta1 expression induced morphological changes there was no change in the levels of fibronectin and E-cadherin compared to C10B cells (Fig. 1b). This result indicates that exogenous expression of Na,K-beta1 in these cells did not reverse the EMT.Fig. 1a Immunoblot analysis of Na,K-ATPase subunits, fibronectin, E-cadherin and actin in parental A2780, C10B and C10B-Na,K-beta cells. Densitometric quantitations are included under each panel. b Relative mRNA expression using quantitative real-time PCR. c Morphological characterization and localization of Na,K-ATPase subunits by phase contrast and epifluorescence microscopy. Bar 20 mum
###end p 33
###begin p 34
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 183 188 180 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">panel</italic>
###xml 190 191 187 188 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 251 252 248 249 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 375 378 372 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bar</italic>
a Immunoblot analysis of Na,K-ATPase subunits, fibronectin, E-cadherin and actin in parental A2780, C10B and C10B-Na,K-beta cells. Densitometric quantitations are included under each panel. b Relative mRNA expression using quantitative real-time PCR. c Morphological characterization and localization of Na,K-ATPase subunits by phase contrast and epifluorescence microscopy. Bar 20 mum
###end p 34
###begin title 35
###xml 49 50 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Increased sensitivity to oxaliplatin in Na,K-beta1 transfected C10B cells
###end title 35
###begin p 36
###xml 159 160 156 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 191 193 185 187 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 291 293 284 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 328 330 320 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 414 416 405 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 579 580 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 589 595 576 582 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 595 596 582 583 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 781 784 765 768 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 804 807 788 791 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 863 864 845 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 872 874 854 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 947 948 922 923 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1152 1153 1121 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1248 1249 1217 1218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1343 1344 1309 1310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 595 1353 582 1319 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><bold>a</bold> Growth inhibition dose response curves for A2780, C10B, C10B-Na,K-&#946; and vector control following a 72&#160;h exposure to oxaliplatin. Data represents percent growth as determined by (OD <sub>570</sub> of treated cells/OD<sub>570</sub> of untreated cells)&#160;&#215;&#160;100. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. IC<sub>50</sub>&#8217;s A2780: 0.2&#160;&#956;M; C10B: 3&#160;&#956;M; C10B-Na,K-&#946;: 1&#160;&#956;M and Vector: 2&#160;&#956;M. <bold>b</bold> Accumulation of Pt in C10B, Vector control, A2780 and C10B-Na,K-&#946; following oxaliplatin treatment. Platinum accumulation following exposure to 100&#160;&#956;M oxaliplatin for 2&#160;h. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. The ** represent statistically highly significant difference compared to C10B or vector (<italic>P</italic>&#160;&lt;&#160;0.001). The difference between A2780 and C10B-Na,K-&#946; is also statistically significant (<italic>P</italic>&#160;=&#160;0.005)</p>
###xml 595 1353 582 1319 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="37"><bold>a</bold> Growth inhibition dose response curves for A2780, C10B, C10B-Na,K-&#946; and vector control following a 72&#160;h exposure to oxaliplatin. Data represents percent growth as determined by (OD <sub>570</sub> of treated cells/OD<sub>570</sub> of untreated cells)&#160;&#215;&#160;100. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. IC<sub>50</sub>&#8217;s A2780: 0.2&#160;&#956;M; C10B: 3&#160;&#956;M; C10B-Na,K-&#946;: 1&#160;&#956;M and Vector: 2&#160;&#956;M. <bold>b</bold> Accumulation of Pt in C10B, Vector control, A2780 and C10B-Na,K-&#946; following oxaliplatin treatment. Platinum accumulation following exposure to 100&#160;&#956;M oxaliplatin for 2&#160;h. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. The ** represent statistically highly significant difference compared to C10B or vector (<italic>P</italic>&#160;&lt;&#160;0.001). The difference between A2780 and C10B-Na,K-&#946; is also statistically significant (<italic>P</italic>&#160;=&#160;0.005)</p></caption>
###xml 1353 1353 1319 1319 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2009_985_Fig2_HTML" id="MO2"/>
###xml 589 1353 576 1319 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="37"><bold>a</bold> Growth inhibition dose response curves for A2780, C10B, C10B-Na,K-&#946; and vector control following a 72&#160;h exposure to oxaliplatin. Data represents percent growth as determined by (OD <sub>570</sub> of treated cells/OD<sub>570</sub> of untreated cells)&#160;&#215;&#160;100. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. IC<sub>50</sub>&#8217;s A2780: 0.2&#160;&#956;M; C10B: 3&#160;&#956;M; C10B-Na,K-&#946;: 1&#160;&#956;M and Vector: 2&#160;&#956;M. <bold>b</bold> Accumulation of Pt in C10B, Vector control, A2780 and C10B-Na,K-&#946; following oxaliplatin treatment. Platinum accumulation following exposure to 100&#160;&#956;M oxaliplatin for 2&#160;h. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. The ** represent statistically highly significant difference compared to C10B or vector (<italic>P</italic>&#160;&lt;&#160;0.001). The difference between A2780 and C10B-Na,K-&#946; is also statistically significant (<italic>P</italic>&#160;=&#160;0.005)</p></caption><graphic position="anchor" xlink:href="280_2009_985_Fig2_HTML" id="MO2"/></fig>
The sensitivity profiles of the parental A2780 cells to oxaliplatin along with the resistant C10B, the C10B-Na,K-beta and the vector control are shown in Fig. 2a. The C10B-Na,K-beta cells (IC50 = 1 muM) were significantly sensitized to oxaliplatin as compared to the resistant C10B cells (IC50 = 3 muM) or the vector control (IC50 = 2 muM) although their sensitivity was not as high as the parental A2780 cells (IC50 = 0.2 muM). The enhanced sensitivity of C10B-Na,K-beta cells to oxaliplatin was statistically significant compared to C10B cells or the vector transfected cells (P < 0.01).Fig. 2a Growth inhibition dose response curves for A2780, C10B, C10B-Na,K-beta and vector control following a 72 h exposure to oxaliplatin. Data represents percent growth as determined by (OD 570 of treated cells/OD570 of untreated cells) x 100. Data represent mean +/- SD, n = 3. IC50's A2780: 0.2 muM; C10B: 3 muM; C10B-Na,K-beta: 1 muM and Vector: 2 muM. b Accumulation of Pt in C10B, Vector control, A2780 and C10B-Na,K-beta following oxaliplatin treatment. Platinum accumulation following exposure to 100 muM oxaliplatin for 2 h. Data represent mean +/- SD, n = 3. The ** represent statistically highly significant difference compared to C10B or vector (P < 0.001). The difference between A2780 and C10B-Na,K-beta is also statistically significant (P = 0.005)
###end p 36
###begin p 37
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 186 189 183 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 209 212 206 209 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 268 269 263 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 277 279 272 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 352 353 340 341 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 557 558 539 540 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 653 654 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 748 749 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
a Growth inhibition dose response curves for A2780, C10B, C10B-Na,K-beta and vector control following a 72 h exposure to oxaliplatin. Data represents percent growth as determined by (OD 570 of treated cells/OD570 of untreated cells) x 100. Data represent mean +/- SD, n = 3. IC50's A2780: 0.2 muM; C10B: 3 muM; C10B-Na,K-beta: 1 muM and Vector: 2 muM. b Accumulation of Pt in C10B, Vector control, A2780 and C10B-Na,K-beta following oxaliplatin treatment. Platinum accumulation following exposure to 100 muM oxaliplatin for 2 h. Data represent mean +/- SD, n = 3. The ** represent statistically highly significant difference compared to C10B or vector (P < 0.001). The difference between A2780 and C10B-Na,K-beta is also statistically significant (P = 0.005)
###end p 37
###begin title 38
###xml 40 41 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
Increased drug accumulation in Na,K-beta1 transfected C10B cells
###end title 38
###begin p 39
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 427 428 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 484 485 478 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 636 637 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 724 725 712 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
We previously reported that C10B cells are deficient in drug accumulation compared to the parental A2780 cells [16]. Since the C10B-Na,K-beta cells exhibit increased sensitivity to oxaliplatin compared to the resistant, C10B cells, we investigated if there was an altered drug accumulation in these cells. C10B-Na,K-beta cells showed about sixfold higher platinum accumulation as compared to the C10B or the vector cells (Fig. 2b). This increase was highly statistically significant (P < 0.001). The amount of platinum accumulated by C10B-Na,K-beta cells was even higher than the parental cells under identical conditions of treatment (P = 0.005). These results suggest that there is a positive correlation between Na,K-beta1 expression and increased platinum accumulation.
###end p 39
###begin title 40
###xml 70 73 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
Confirmation of the sensitization and drug accumulation phenomenon in MSV-MDCK-beta subunit cells
###end title 40
###begin p 41
###xml 65 66 62 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 252 253 246 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 299 300 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 337 338 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 445 447 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 667 668 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 727 728 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 806 807 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 835 836 814 815 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 918 924 897 903 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 924 925 903 904 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 964 965 940 941 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 985 986 961 962 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1164 1167 1137 1140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 1187 1190 1160 1163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 1254 1255 1225 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1263 1265 1234 1236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 1308 1309 1274 1275 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1454 1455 1414 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1515 1516 1475 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 924 1525 903 1485 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="42"><bold>a</bold> Immunoblot showing levels of Na,K-&#946;<sub>1</sub> in MSV-MDCK cells. <bold>b</bold> Growth inhibition dose response curves for MSV-MDCK vector and MSV-MDCK-&#946;-subunit following 72&#160;h exposure to oxaliplatin. Data represents percent growth as determined by (OD <sub>570</sub> of treated cells/OD<sub>570</sub> of untreated cells)&#160;&#215;&#160;100. Data expressed as mean&#160;&#177;&#160;SE where <italic>n</italic>&#160;=&#160;3. IC<sub>50</sub>&#8217;s Vector: 18&#160;&#956;M, MSV-MDCK-&#946;: 2.5&#160;&#956;M. <bold>c</bold> Platinum accumulation following exposure to 100&#160;&#956;M oxaliplatin for 2&#160;h in MSV-MDCK vector and MSV-MDCK-&#946; cells. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. The * represent statistically significant difference (<italic>P</italic>&#160;=&#160;0.016)</p>
###xml 924 1525 903 1485 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="42"><bold>a</bold> Immunoblot showing levels of Na,K-&#946;<sub>1</sub> in MSV-MDCK cells. <bold>b</bold> Growth inhibition dose response curves for MSV-MDCK vector and MSV-MDCK-&#946;-subunit following 72&#160;h exposure to oxaliplatin. Data represents percent growth as determined by (OD <sub>570</sub> of treated cells/OD<sub>570</sub> of untreated cells)&#160;&#215;&#160;100. Data expressed as mean&#160;&#177;&#160;SE where <italic>n</italic>&#160;=&#160;3. IC<sub>50</sub>&#8217;s Vector: 18&#160;&#956;M, MSV-MDCK-&#946;: 2.5&#160;&#956;M. <bold>c</bold> Platinum accumulation following exposure to 100&#160;&#956;M oxaliplatin for 2&#160;h in MSV-MDCK vector and MSV-MDCK-&#946; cells. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. The * represent statistically significant difference (<italic>P</italic>&#160;=&#160;0.016)</p></caption>
###xml 1525 1525 1485 1485 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2009_985_Fig3_HTML" id="MO3"/>
###xml 918 1525 897 1485 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="42"><bold>a</bold> Immunoblot showing levels of Na,K-&#946;<sub>1</sub> in MSV-MDCK cells. <bold>b</bold> Growth inhibition dose response curves for MSV-MDCK vector and MSV-MDCK-&#946;-subunit following 72&#160;h exposure to oxaliplatin. Data represents percent growth as determined by (OD <sub>570</sub> of treated cells/OD<sub>570</sub> of untreated cells)&#160;&#215;&#160;100. Data expressed as mean&#160;&#177;&#160;SE where <italic>n</italic>&#160;=&#160;3. IC<sub>50</sub>&#8217;s Vector: 18&#160;&#956;M, MSV-MDCK-&#946;: 2.5&#160;&#956;M. <bold>c</bold> Platinum accumulation following exposure to 100&#160;&#956;M oxaliplatin for 2&#160;h in MSV-MDCK vector and MSV-MDCK-&#946; cells. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. The * represent statistically significant difference (<italic>P</italic>&#160;=&#160;0.016)</p></caption><graphic position="anchor" xlink:href="280_2009_985_Fig3_HTML" id="MO3"/></fig>
###xml 204 207 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 342 345 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 358 361 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 512 515 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 781 784 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 969 972 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 1030 1033 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 1050 1053 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 1284 1287 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 1385 1388 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 1405 1408 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
Sensitization to oxaliplatin by exogenous expression of Na,K-beta1 was investigated in another cell line to test whether this phenomenon is specific to ovarian cells or occurs in other cell type as well. MSV-MDCK cells expresses low levels of Na,K-beta1 and are highly invasive and metastatic (Fig. 3a). Exogenous expression of Na,K-beta1 in MSV-MDCK cells (MSV-MDCK-beta subunit) reduced their motility, invasiveness and tumorigenic potential [28]. Cytotoxicity and platinum accumulation studies indicated that MSV-MDCK-beta subunit cells were more sensitive to oxaliplatin as compared to the parental cells carrying the vector and do not express this protein (Fig. 3b). Further studies confirmed a statistically significant (P < 0.05) increase in the accumulation of platinum in MSV-MDCKbeta cells (Fig. 3c) indicating that Na,K-beta1 expression facilitates oxaliplatin uptake and increases sensitivity to this drug.Fig. 3a Immunoblot showing levels of Na,K-beta1 in MSV-MDCK cells. b Growth inhibition dose response curves for MSV-MDCK vector and MSV-MDCK-beta-subunit following 72 h exposure to oxaliplatin. Data represents percent growth as determined by (OD 570 of treated cells/OD570 of untreated cells) x 100. Data expressed as mean +/- SE where n = 3. IC50's Vector: 18 muM, MSV-MDCK-beta: 2.5 muM. c Platinum accumulation following exposure to 100 muM oxaliplatin for 2 h in MSV-MDCK vector and MSV-MDCK-beta cells. Data represent mean +/- SD, n = 3. The * represent statistically significant difference (P = 0.016)
###end p 41
###begin p 42
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 40 41 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 61 62 58 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 240 243 234 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 263 266 257 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">570</sub>
###xml 330 331 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 339 341 331 333 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 384 385 371 372 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 530 531 511 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 591 592 572 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 45 48 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 106 109 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 126 129 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 360 363 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 461 464 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 481 484 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
a Immunoblot showing levels of Na,K-beta1 in MSV-MDCK cells. b Growth inhibition dose response curves for MSV-MDCK vector and MSV-MDCK-beta-subunit following 72 h exposure to oxaliplatin. Data represents percent growth as determined by (OD 570 of treated cells/OD570 of untreated cells) x 100. Data expressed as mean +/- SE where n = 3. IC50's Vector: 18 muM, MSV-MDCK-beta: 2.5 muM. c Platinum accumulation following exposure to 100 muM oxaliplatin for 2 h in MSV-MDCK vector and MSV-MDCK-beta cells. Data represent mean +/- SD, n = 3. The * represent statistically significant difference (P = 0.016)
###end p 42
###begin title 43
Oxaliplatin accumulation and resulting sensitization to oxaliplatin is independent of the pump function of Na,K-ATPase
###end title 43
###begin p 44
###xml 391 393 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 526 527 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 694 700 687 693 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 700 701 693 694 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 865 866 851 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 872 873 858 859 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1036 1037 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 700 1041 693 1020 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45"><bold>a</bold> Accumulation of platinum in C10B-Na,K-&#946; cells exposed to oxaliplatin (100&#160;&#956;M for 2&#160;h) with and without ouabain (50&#160;&#956;M) treatment. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. <bold>b</bold> Accumulation of platinum in MSV-MDCK-&#946; cells exposed to oxaliplatin (100&#160;&#956;M for 2&#160;h) with and without ouabain (50&#160;&#956;M) treatment. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3</p>
###xml 700 1041 693 1020 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45"><bold>a</bold> Accumulation of platinum in C10B-Na,K-&#946; cells exposed to oxaliplatin (100&#160;&#956;M for 2&#160;h) with and without ouabain (50&#160;&#956;M) treatment. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. <bold>b</bold> Accumulation of platinum in MSV-MDCK-&#946; cells exposed to oxaliplatin (100&#160;&#956;M for 2&#160;h) with and without ouabain (50&#160;&#956;M) treatment. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3</p></caption>
###xml 1041 1041 1020 1020 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="280_2009_985_Fig4_HTML" id="MO4"/>
###xml 694 1041 687 1020 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="45"><bold>a</bold> Accumulation of platinum in C10B-Na,K-&#946; cells exposed to oxaliplatin (100&#160;&#956;M for 2&#160;h) with and without ouabain (50&#160;&#956;M) treatment. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3. <bold>b</bold> Accumulation of platinum in MSV-MDCK-&#946; cells exposed to oxaliplatin (100&#160;&#956;M for 2&#160;h) with and without ouabain (50&#160;&#956;M) treatment. Data represent mean&#160;&#177;&#160;SD, <italic>n</italic>&#160;=&#160;3</p></caption><graphic position="anchor" xlink:href="280_2009_985_Fig4_HTML" id="MO4"/></fig>
###xml 149 152 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 367 372 <span type="species:ncbi:9606">human</span>
###xml 902 905 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
In order to determine whether the Na,K-ATPase enzyme activity determines the changes in altered drug accumulation, both C10B-Na,K-beta cells and the MSV-MDCK-beta subunit cells were treated with ouabain, a pharmacological inhibitor of Na,K-ATPase. Ouabain at 50 muM concentration that we used in our experiments is known to completely inhibit Na,K-ATPase activity in human and canine cells [19]. The results show that there is no significant difference in platinum accumulation in ouabain treated versus untreated cells (Fig. 4a, b), suggesting that the pump function of Na,K-ATPase might not be involved in the observed increases in drug uptake and sensitization to oxaliplatin in these cells.Fig. 4a Accumulation of platinum in C10B-Na,K-beta cells exposed to oxaliplatin (100 muM for 2 h) with and without ouabain (50 muM) treatment. Data represent mean +/- SD, n = 3. b Accumulation of platinum in MSV-MDCK-beta cells exposed to oxaliplatin (100 muM for 2 h) with and without ouabain (50 muM) treatment. Data represent mean +/- SD, n = 3
###end p 44
###begin p 45
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 165 166 158 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 172 173 165 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 336 337 322 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 202 205 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
a Accumulation of platinum in C10B-Na,K-beta cells exposed to oxaliplatin (100 muM for 2 h) with and without ouabain (50 muM) treatment. Data represent mean +/- SD, n = 3. b Accumulation of platinum in MSV-MDCK-beta cells exposed to oxaliplatin (100 muM for 2 h) with and without ouabain (50 muM) treatment. Data represent mean +/- SD, n = 3
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 37 38 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 265 266 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 305 306 296 297 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 479 480 467 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
The exogenous expression of Na,K-beta1 in the oxaliplatin resistant C10B cells increased the uptake and cell sensitivity to the drug. Increased uptake and sensitization of cells to the drug were independently confirmed in kidney carcinoma cells expressing Na,K-beta1. Our data also suggests that Na,K-beta1 expression increases sensitivity to oxaliplatin independent of Na,K-ATPase pump function. Thus, these results for the first time reveal that reduced expression of Na,K-beta1 protein is associated with oxaliplatin resistance and that increasing its levels enhances oxaliplatin sensitivity of carcinoma cells.
###end p 47
###begin p 48
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 1289 1291 1289 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 1527 1529 1527 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1740 1742 1740 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1921 1922 1921 1922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 1924 1926 1924 1926 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 214 219 <span type="species:ncbi:9606">human</span>
Reduced drug accumulation is one of the commonly described mechanisms for platinum drug resistance in many studies with a strong correlation between platinum accumulation and relative resistance as demonstrated in human hepatoma BEL7404 cells with increasing acquired resistance to cisplatin [20], and primary bladder cancer cell lines with intrinsic resistance to cisplatin [23]. While there is a consensus that drug accumulation is a major determinant of platinum drug sensitivity, the mechanisms involved in uptake are still not well understood. In addition, much of the work to date is on the prototype drug cisplatin and relatively fewer reports exist on the uptake of other platinum analogs including oxaliplatin. In a recent review, Hall et al. [14] discuss the current evidence for how cisplatin enters the cells, its potential extrusion out of cells and cellular changes in resistance including information that is available for the platinum analogs. Most of the evidence suggests that cisplatin uptake and possibly of other analogs involves multiple mechanisms including diffusion, CTR1 copper influx transporter mediated uptake (of cisplatin but not oxaliplatin) [29], and organic cation transporters (SLC family members OCT1 and 2) which may be involved in oxaliplatin uptake [37]. It was suggested that the potential speciation in various media of platinum analogs that imparts the charged versus neutral characteristics to these drugs could in addition dictate which mechanism of transport may play a major role [14]. In the absence of evidence for changes in physicochemical properties of membranes accounting for altered diffusion in resistant cells, the available evidence only points to alterations in transport proteins [14]. A potential role for copper efflux transporters ATP7A/7B and glutathione conjugate pump (GS-X family) in the efflux of cisplatin and resistance to the drug has been described [8, 22].
###end p 48
###begin p 49
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 120 122 120 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 323 324 323 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 470 471 470 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 767 768 767 768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1115 1116 1115 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1260 1261 1260 1261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1459 1460 1456 1457 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1596 1597 1590 1591 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1824 1826 1818 1820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 244 249 <span type="species:ncbi:9606">human</span>
###xml 785 790 <span type="species:ncbi:9606">human</span>
###xml 825 830 <span type="species:ncbi:9606">human</span>
Na,K-ATPase enzyme function mediated transport has also been suggested as a potential mechanism in cisplatin uptake [4, 14]. While the experiments with ouabain inhibition indicated a potential role for Na,K-ATPase in cisplatin uptake into 2008 human ovarian carcinoma cells and their cisplatin resistant variant A2780/DDP [4], no differences in Na,K-ATPase activity between cisplatin sensitive and resistant cells have been observed [3]. Their studies suggested for a Na+-dependent transporter for cisplatin. In separate experiments primarily aimed at disrupting the sodium gradient they concluded that it is the sodium gradient dissipation, which is also resulting from the inhibition of Na,K-ATPase activity by ouabain that is affecting the cisplatin accumulation [3]. In a panel of human small cell lung cancer (SCLC) and human non-small cell lung cancer (NSCLC) cell lines all expressing Na,K-ATPase activity, ouabain inhibition lowered cisplatin accumulation in NSCLC cell lines, but not in SCLC, suggesting that other factors distinct from the pump activity may have an impact on cisplatin uptake into cells [5]. A more recent report connects Na,K-ATPase activity and not ATP-7A and ATP-7B in cisplatin sensitivity in oral squamous cell carcinoma cells [1]. At the moment it is unclear what the exact role of Na,K-ATPase function is in cisplatin uptake, or a role if there is any for oxaliplatin uptake. In the two cell models transfected with Na,K-beta1, we did not observe any change in platinum uptake following ouabain treatment. In our experiments, by increased expression of Na,K-beta1 in ovarian carcinoma cells, restoration to sensitivity was achieved partially, but not completely indicating the multi-factorial nature of resistance such as high levels of glutathione in C10B cells that we described earlier [16].
###end p 49
###begin p 50
###xml 366 368 366 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 494 495 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 497 499 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 609 611 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 661 662 655 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 754 755 745 746 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1062 1063 1050 1051 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1183 1184 1171 1172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1186 1188 1174 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1210 1212 1198 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1259 1260 1244 1245 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1361 1362 1346 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1364 1366 1349 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 1368 1370 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 1416 1417 1398 1399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1546 1547 1525 1526 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1775 1776 1751 1752 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1928 1929 1901 1902 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2175 2176 2145 2146 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 2295 2296 2262 2263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1027 1030 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
###xml 1980 1988 <span type="species:ncbi:9606">patients</span>
The parental A2780 cells are adherent to each other and show epithelial phenotype. The C10B cells on the other hand were of mesenchymal phenotype indicating that during the selection of oxaliplatin resistance the A2780 cells have undergone EMT. This is further confirmed by the increased levels of fibronectin in C10B cells (present study), positivity for vimentin [16] and up-regulated expression of genes of extracellular matrix, such as matrix metalloproteinases, integrin alpha and TGF-beta2 [34], genes described to be either part of EMT and/or part of the extracellular matrix mediated drug resistance [10]. Interestingly, although expression of Na,K-beta1 induced an adherent phenotype as revealed by the change in the morphology of C10B-Na,K-beta1 cells, there was no change in the levels of fibronectin compared to C10B cells. This result suggests that the reversal of EMT, i.e., mesenchymal to epithelial transition (MET) has not taken place in these cells at least at the molecular level. This is also the case with MSV-MDCK cells expressing Na,K-beta1. These cells have not reverted their mesenchymal phenotype but are more adherent to each other, show reduced motility [6, 28] and tumorigenicity [18]. We and others recently showed that Na,K-beta1 is a cell-cell adhesion molecule and increases cell-cell contact when expressed in carcinoma cells [7, 31, 33]. Although the mechanism/s by which Na,K-beta1 increases sensitivity to oxaliplatin is not known, it is tempting to speculate that the cell-cell adhesion function of Na,K-beta1 might be involved in this process. It is possible that cells that are contact naive are less sensitive to drugs compared to cells adherent to each other. Future experiments are necessary to unravel mechanisms by which Na,K-beta1 is increasing the drug uptake and sensitizing cells for oxaliplatin. However, the current findings have immense therapeutic potential. First, Na,K-beta1 levels could be used as a biomarker for screening patients that would respond better to platinum based chemotherapy. Secondly, it may be possible to target the cancer cells which have become drug-insensitive by increasing the levels of Na,K-beta1 in these cells using targeted gene therapy approaches. We suggest that ability to increase the expression of Na,K-beta1 should have significant therapeutic value for treating drug-insensitive malignancies.
###end p 50
###begin p 51
This work was supported in part by NCICA109619 (LP) and NIHDK56216 (AR). We acknowledge the support of Comprehensive Cancer Center grant NCICA10656 for the Pharmacokinetics/Pharmacodynamics Core Facility usage.
###end p 51
###begin p 52
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 52
###begin title 53
References
###end title 53
###begin article-title 54
Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na(+), K(+)-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B
###end article-title 54
###begin article-title 55
Mechanisms of acquired resistance to cisplatin
###end article-title 55
###begin article-title 56
###xml 105 110 <span type="species:ncbi:9606">human</span>
Role of the Na+,K(+)-adenosine triphosphatase in the accumulation of cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells
###end article-title 56
###begin article-title 57
###xml 73 78 <span type="species:ncbi:9606">human</span>
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells
###end article-title 57
###begin article-title 58
###xml 101 106 <span type="species:ncbi:9606">human</span>
Significance of Na+,K(+)-ATPase on intracellular accumulation of cis-diamminedichloroplatinum(II) in human non-small-cell but not in small-cell lung cancer cell lines
###end article-title 58
###begin article-title 59
Novel role for Na,K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility
###end article-title 59
###begin article-title 60
Janus model of the Na,K-ATPase beta-subunit transmembrane domain: distinct faces mediate alpha/beta assembly and beta-beta homo-oligomerization
###end article-title 60
###begin article-title 61
Do cMOAT (MRP2), other MRP homologues and LRP play a role in MDR?
###end article-title 61
###begin article-title 62
Altered glutathione metabolism in oxaliplatin resistant A2780 ovarian carcinoma cells
###end article-title 62
###begin article-title 63
Integrins and extracellular matrix
###end article-title 63
###begin article-title 64
Repression of Na,K-ATPase beta1-subunit by the transcription factor snail in carcinoma
###end article-title 64
###begin article-title 65
Insights into mechanisms of cisplatin resistance and potential for its clinical reversal
###end article-title 65
###begin article-title 66
The role of epithelial-mesenchymal transition in cancer pathology
###end article-title 66
###begin article-title 67
The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy
###end article-title 67
###begin article-title 68
In vitro studies on the mechanisms of oxaliplatin resistance
###end article-title 68
###begin article-title 69
Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10
###end article-title 69
###begin article-title 70
Molecular requirements for epithelial-mesenchymal transition during tumor progression
###end article-title 70
###begin article-title 71
Evidence for a potential tumor suppressor role for the Na,K-ATPase beta1-subunit
###end article-title 71
###begin article-title 72
###xml 57 60 <span type="species:ncbi:10116">rat</span>
Comparison of the substrate dependence properties of the rat Na,K-ATPase alpha 1, alpha 2, and alpha 3 isoforms expressed in HeLa cells
###end article-title 72
###begin article-title 73
###xml 126 131 <span type="species:ncbi:9606">human</span>
Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines
###end article-title 73
###begin article-title 74
Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells
###end article-title 74
###begin article-title 75
Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper
###end article-title 75
###begin article-title 76
###xml 92 97 <span type="species:ncbi:9606">human</span>
Accumulation of intracellular platinum is correlated with intrinsic cisplatin resistance in human bladder cancer cell lines
###end article-title 76
###begin article-title 77
Oxalato-platinum or l-OHP, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
###end article-title 77
###begin article-title 78
Molecular mechanisms of resistance and toxicity associated with platinating agents
###end article-title 78
###begin article-title 79
Interactions of tight junctions with membrane channels and transporters
###end article-title 79
###begin article-title 80
###xml 88 91 <span type="species:ncbi:11809?0.5289256198347108|species:ncbi:10821?0.1652892561983471">MSV</span>
Na,K-ATPase beta1-subunit increases the translation efficiency of the alpha1-subunit in MSV-MDCK cells
###end article-title 80
###begin article-title 81
Na,K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility
###end article-title 81
###begin article-title 82
Role of copper transporters in the uptake and efflux of platinum containing drugs
###end article-title 82
###begin article-title 83
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells
###end article-title 83
###begin article-title 84
The polarized expression of Na+,K+-ATPase in epithelia depends on the association between beta-subunits located in neighboring cells
###end article-title 84
###begin article-title 85
Mechanisms of metastasis: epithelial to mesenchymal transition and contribution of tumor microenvironment
###end article-title 85
###begin article-title 86
The role of the beta1 subunit of the Na,K-ATPase and its glycosylation in cell-cell adhesion
###end article-title 86
###begin article-title 87
Gene expression profiling of a clonal isolate of oxaliplatin resistant ovarian carcinoma cell line A2780/C10
###end article-title 87
###begin article-title 88
Oxaliplatin. A review of its use in the management of metastatic colorectal cancer
###end article-title 88
###begin article-title 89
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines
###end article-title 89
###begin article-title 90
Organic cation transporters are determinants of oxaliplatin cytotoxicity
###end article-title 90

